Prøve GULL - Gratis

Countering Obesity with Drugs Vs Viable Alternatives

Bio Spectrum

|

BioSpectrum India June 2025

A sizable obese population in India is a free ground for multinational pharma companies to launch various anti-obesity drugs.

Countering Obesity with Drugs Vs Viable Alternatives

Let aside the affordability issue, these drugs can be a game changer. However, severe side effects lurk in the background. Alternative treatment and fundamental lifestyle changes can be seen as an alternative mode to counter obesity. Let's examine the available and prospective obesity therapeutics.

The current state of obesity in India is alarming. As was evident from Prime Minister Narendra Modi's 119th Maan Ki Baat, where he cautioned against the rise in obesity cases that have doubled in the last few years. A major concern during his speech was how children are getting affected more. Union Minister Dr Jitendra Singh, a renowned Diabetologist, also raised alarms while underscoring the urgent need for a multifaceted and collective approach to combat the growing obesity crisis in India.

India's stint with obesity started in the last 20th century with people getting addicted to sugary drinks, junk foods etc. Rapid urbanisation, economic development, lifestyle changes and less physical activity all contributed to a rise in the obese population. Obesity is linked with stigma, and many encounter fat shaming. It leads to psychological stress. This apart, an obese person is vulnerable to various health issues like heart disease, type 2 diabetes, high blood pressure, cancer, sleep apnea, etc.

Launch of anti-obesity drugs

Seeing this as a strategy to market anti-obesity drugs, many multinational pharmaceutical companies are in a rat race to launch various products. With the launch of weight-loss drugs in the Indian market, the debate around pharmacological obesity treatment has intensified.

Seeking an opportunity, the US pharma major, Eli Lilly, recently launched Mounjaro. It is a single-dose vial presentation and has received marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO). The company went ahead and also launched a campaign to combat the associated stigma with obesity.

FLERE HISTORIER FRA Bio Spectrum

Bio Spectrum

Bio Spectrum

WHO certifies Suriname malaria-free

Suriname became the first country in the Amazon region to receive malaria-free certification from the World Health Organization (WHO).

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

Torrent Pharma buys controlling stake in JB Pharma from KKR for Rs 25,689 Cr valuation

Ahmedabad-based Torrent Pharmaceuticals and global investment firm KKR have announced that Torrent has entered into definitive agreements to acquire controlling stake in Mumbai-based J. B. Chemicals and Pharmaceuticals (JB Pharma) from KKR at an Equity Valuation of Rs 25,689 crore (on fully diluted basis), followed by a merger of the two entities.

time to read

1 min

August 2025

Bio Spectrum

Suraksha Diagnostics injects Rs 22 Cr to establish Eastern India's largest genomics lab

Suraksha Diagnostics, one of the leading diagnostics chains in Eastern India, has launched one of the largest and a state-of-theart genomics lab in Eastern India.

time to read

1 min

August 2025

Bio Spectrum

Illumina buys SomaLogic for $425 M to accelerate proteomics business

Illumina, Inc. has entered into a definitive agreement with Standard BioTools under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties.

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

Kashmik Formulation to expand capacity, eyes Rs 100 Cr revenue in FY26

Kashmik Formulation, a pharmaceutical manufacturing company headquartered in Ahmedabad, has announced significant expansion plans aimed at increasing production capacity, strengthening its presence in international markets, and enhancing operational efficiencies through automation.

time to read

1 min

August 2025

Bio Spectrum

WHO highlights risks associated with use of semaglutide medicines

The World Health Organisation (WHO) is alerting healthcare professionals and regulatory authorities to the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of semaglutide medicinesOzempic, Rybelsus, and Wegovy.

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

Lamark Biotech secures Rs 6.5 Cr to accelerate development of thermostable insulin

Lamark Biotech, an innovation-led biopharma startup, has raised Rs 6.5 crore in a PreSeries A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Dr Vinayender Tulla, Dr Nita Roy, and Venkataraman KNK, domain experts of IAN's angel investors led the round.

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

AstraZeneca invests Rs 166 Cr to expand Global Hub in Bengaluru

AstraZeneca, a global, science-led biopharmaceutical company, has announced the expansion of its state-of-the-art Global Hub in Bengaluru, strengthening its presence in India.

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

Novo Nordisk launches injectable Semaglutide for weight management in India

Novo Nordisk, a leading global healthcare company headquartered in Denmark with over a 100-year legacy of chronic disease care, has announced the launch of Wegovy (injectable Semaglutide) in India.

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

Can Policy Reforms & Investments Trigger India's MedTech MAKEOVER?

India's MedTech sector has long been import-dependent. The Centre is now working to change this by positioning the country as an export-oriented manufacturing hub. A series of policies and investments have been introduced to support this shift. Have these made an impact? What steps are necessary to strengthen India's position in the global medical technology (MedTech) landscape? Let's find out.

time to read

12 mins

August 2025

Listen

Translate

Share

-
+

Change font size